OTC · RSPI
RespireRx Pharmaceuticals Inc.
$0.00$0.00 (0.0%)
RespireRx Pharmaceuticals Inc.’s quoted price sits in the upper half of its reported 52-week range, 33.33% below the high.
Loading market information…
OTC · IPIX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 07:21 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Innovation Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.6% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Innovation Pharmaceuticals Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Innovation Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to the development of small molecule therapies. Its pipeline targets a range of medical areas, including inflammatory diseases, cancer, dermatology, and infectious conditions. The company's lead drug candidate, Brilacidin, is currently in development for treating oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. Furthermore, Innovation Pharmaceuticals is advancing Kevetrin, an anti-cancer compound being investigated for ovarian cancer. The company holds a license agreement with Alfasigma S.p.A. and has a collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. Established in 2005 and headquartered in Wakefield, Massachusetts, the firm operated as Cellceutix Corporation until its name change to Innovation Pharmaceuticals Inc. in June 2017.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:52 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.00$0.00 (0.0%)
RespireRx Pharmaceuticals Inc.’s quoted price sits in the upper half of its reported 52-week range, 33.33% below the high.
$0.01$0.00 (0.0%)
ChitogenX Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.01$0.00 (0.0%)
Viracta Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.8% below the high.
$0.00$0.00 (0.0%)
Actavia Life Sciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 87.5% below the high.
$0.00$0.00 (0.0%)
MedGen, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Lift & Co. Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Nascent Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.85% below the high.
$0.00$0.00 (0.0%)
RegeneRx Biopharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.33% below the high.
